Key result
While pregnancy is contraindicated in pulmonary hypertension, multidisciplinary management and careful use of specific pharmacotherapy can achieve favorable outcomes for mother and child.
Why the study?
What is the recommended pharmacotherapy for pulmonary hypertension during pregnancy and the postpartum period?
What is the recommended pharmacotherapy for pulmonary hypertension during pregnancy and the postpartum period?
This review highlights that while pregnancy is contraindicated in pulmonary hypertension, careful multidisciplinary management and specific pharmacotherapy can lead to favorable outcomes in women who choose to continue their pregnancy.
Pregnancy in women with pulmonary hypertension is associated with a high risk of poor outcomes and high maternal mortality rates, therefore contraindicated in this category of patients. Yet the world has accumulated some experience of pregnancy in women with pulmonary hypertension, who refused abortion, or in whom the disease was diagnosed in later stages of gestation. In this paper results of randomized and observational studies of the main and supportive pharmacotherapy in pulmonary hypertension are given, characteristics of modern drugs for the treatment of pulmonary hypertension and data on their safety during pregnancy are recommended, as well as expert opinion on drug therapy in pregnant women with pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Ушкалова et al. (2013) conducted a review in Pulmonary hypertension during pregnancy. Pharmacotherapy for pulmonary hypertension (prostacyclin analogues, PDE-5 inhibitors, endothelin receptor antagonists, calcium channel blockers) was evaluated. While pregnancy is contraindicated in pulmonary hypertension, multidisciplinary management and careful use of specific pharmacotherapy can achieve favorable outcomes for mother and child.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: